Full-Time

Associate Director Regulatory Affairs

Oncology

GSK

GSK

10,001+ employees

Develops medicines, vaccines, and consumer health

Compensation Overview

$138.8k - $231.3k/yr

+ Bonus + Long Term Incentive

North Bethesda, MD, USA + 3 more

More locations: Phoenixville, PA, USA | Durham, NC, USA | Waltham, MA, USA

Hybrid

Hybrid (remote & on-site) in listed US locations.

PharmD, PhD, MD

Category
Legal & Compliance (1)

Get referred to GSK

See people who can refer or advise you

Requirements
  • Experience of all phases of the drug development process in regulatory affairs preferred.
  • Experience leading regional development, submission and approval activities in local region(s).
  • Experience with clinical trial and licensing requirements in all major countries in the region and ideally knowledge of other key Agency processes globally.
Responsibilities
  • Proactively develop regulatory strategy that will deliver the needs of the local region(s), taking into account the needs of other regions globally.
  • Implement the regional strategy(s) in support of the project globally.
  • Lead regulatory interactions and review processes in local region.
  • Ensure appropriate interaction with global/regional counterparts and commercial teams in local region.
  • Ensure compliance with global/ regional requirements at all stages of product life.
  • Ideally assess precedent, regulatory intelligence and competitive environment from a regulatory perspective for the region and the impact this will have on the regulatory strategy for an asset.
Desired Qualifications
  • Advanced Scientific Degree (PhD, MD, PharmD).
  • Minimum of two years of experience in Oncology (Hematology or Solid Tumor) regulatory affairs.
  • Strong matrix working skills, with the ability to facilitate dialogue and idea contribution among team members.
  • Proactive problem-solving skills to identify and resolve project or team issues in advance.
  • Creative regulatory problem-solving capabilities, balancing agency expectations and compliance.
  • A focus on continuous improvement and excellence, with the ability to challenge current processes and recommend strategic changes.
  • Ability to develop networks within GSK to secure support and achieve project outcomes.

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales reached £8.4 billion, up 5%, beating expectations.
  • Specialty medicines rose 14%, led by oncology, respiratory, and HIV strength.
  • GSK's £400 million Cambridge hub and 20+ Phase III starts should sharpen innovation.

What critics are saying

  • Camlipixant died on July 17, 2026, triggering £1.3 billion Q2 impairments.
  • Dolutegravir loses exclusivity from 2028 to 2030, threatening GSK's biggest HIV cash engine.
  • Stevenage closes by 2029; if oncology disappoints, GSK becomes a slower-growth specialty incumbent.

What makes GSK unique

  • GSK still spans vaccines, HIV, oncology, and respiratory across 130 countries.
  • Luke Miels' July 28, 2026 strategy pushes 20+ Phase III starts and faster execution.
  • The Cambridge Biomedical Campus move embeds GSK inside Europe's deepest life-sciences cluster.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Company News

Yahoo Finance
Aug 6th, 2026
GSK prelet drives UK lab space demand to record 1.2M sq ft despite vacancies hitting 14.3%

UK laboratory space demand hit a record high, with rolling four-quarter take-up exceeding 1.2 million square feet in Q3 2026, according to CoStar data. The surge was driven by GSK's 300,000-square-foot prelet at Cambridge Biomedical Campus. Cambridge has led activity in 2026, with year-to-date leasing volumes above 180,000 square feet, nearly double Oxford's total. The first seven months of 2026 saw almost 500,000 square feet leased, matching the previous record year in 2015. However, UK laboratory vacancies reached a record 14.3% in Q2 2026, more than doubling in two years. The rise followed 1.8 million square feet of new lab space delivered across the Golden Triangle over the past two years. Construction activity has slowed significantly, with less than 130,000 square feet started on site in 2026, reducing the UK construction pipeline to around 3 million square feet.

Property Week
Aug 4th, 2026
Nearly 800,000 sq ft of Golden Triangle lab space under offer after Q2 dip.

Nearly 800,000 sq ft of Golden Triangle lab space under offer after Q2 dip. Just under 800,000 sq ft of commercial space was under offer across the London-Oxford-Cambridge Golden Triangle at the end of July, promising a return to form for the market after a dip in leasing activity in Q2, according to Cushman & Wakefield. GSK is agreed to take a 300,000 sq ft new R&D centre at Discovery Drive, Cambridge Biomedical Campus Life science take-up across the Golden Triangle stood at 175,000 sq ft in Q2, 8% below the five-year quarterly average and 57% below the surge in Q1. However, at the close of Q2, 779,200 sq ft was under offer, including GSK's proposed deal for a 300,000 sq ft new R&D centre at Discovery Drive on the Cambridge Biomedical Campus. Cushman & Wakefield said that should these deals be completed as expected, leasing in H2 2026 could return to the stronger levels recorded across the previous two quarters. In Q2, London lead leasing activity, accounting for 56% of the quarterly volume with five deals totalling 98,300 sq ft. The majority of this came from an unnamed occupier taking the 85,000 sq ft Jahn Court in the Regent Quarter Campus. Cambridge recorded 48,500 sq ft across three deals, while two deals in oxford added 28,200 sq ft. Prime quoting rents held steady across the three cities for the fifth consecutive quarter, at £140/sq ft in London, £77/sq ft in Cambridge and £70/sq ft in Oxford. C&W rates all three markets as 'under pressure' as space remains constrained, with elevated construction and financing costs, geopolitical uncertainty and higher vacancy rates constraining speculative development. Despite this, at the close of Q2, 2.9m sq ft of laboratory space was under construction across the Golden Triangle, with around 2.2m sq ft of speculative space scheduled for completion over the next three years. Development continues to moderate, the report said, with the volume under construction at its lowest level since Q1 2024. Planning consent has been secured for a further 4.2m sq ft, which should be developed by 2029. The report says UK life science companies raised just over £2bn in venture capital in Q2, the strongest quarter for VC investment in over a year, up 135% on Q1 and 102% above the five-year quarterly average. Golden Triangle life sciences investment volumes totalled £160m from two transactions, the largest being British Land's acquisition of the Life Sciences REIT portfolio for £150m, while Wrenbridge and Investec Realis acquired a three-acre site in North Cambridge from the Coulson Building Group for £10m, with plans to develop it into a commercial and life sciences hub. C&W said investment during H1 reflected a challenging environment and while there are early signs of improving sentiment, it warned that expectations of a marked recovery "should remain measured".

Yahoo Finance
Aug 1st, 2026
GSK opens $1.3B+ Cambridge research hub and partners with Relation Therapeutics

GSK will establish a new global R&D centre on the Cambridge Biomedical Campus in the UK, accommodating over 1,000 scientists. The facility will support closer collaboration with nearby research institutions and biotech companies. The pharmaceutical firm has also agreed a research collaboration with Relation Therapeutics. The partnership will use advanced cellular biology models and large-scale data generation. The moves signal GSK's increased focus on data-driven and AI-supported drug discovery. The Cambridge location places the company at the centre of one of Europe's leading life sciences hubs. GSK shares currently trade at £19.32, approximately 10% below the £21.42 analyst consensus target.

World News Index
Jul 30th, 2026
GSK to establish £400 million flagship R&D centre in Cambridge.

GSK to establish £400 million flagship R&D centre in Cambridge. By The Rutherford Post UK on July 30, 2026, 5:44 pm, BST Pharmaceutical giant GSK is set to establish a major new global R&D centre in Cambridge, UK, as part of its plan to accelerate its R&D pipeline. The new 300,000 square foot site, located on the Cambridge Biomedical Campus, will be home to GSK's R&D operations in the UK and more than 1,000 GSK scientists. The campus is one of the largest biomedical campuses in Europe, providing direct access to a world-class ecosystem of biomedical research, patient care and academia. The new location will feature state-of-the-art, tech-enabled labs and infrastructure to support research in GSK's focus areas of Oncology, Respiratory, Hepatology, Vaccines and HIV. The site will also provide opportunities for collaboration with existing GSK partners and collaborations, including the Cambridge Centre for Data-Driven Discovery and the Cambridge-GSK Translational Immunology Collaboration. GSK's Chief Executive Officer, Luke Miels, said the investment will accelerate the company's R&D and help deliver new, competitive products. Tony Wood, Chief Scientific Officer, added that the campus provides exceptional opportunities for collaboration, citing the leading universities, hospitals and biotech companies already based there. The site in Cambridge is currently in development by Prologis and is expected to be part of GSK's wider UK network of collaboration with leading academic institutions and pioneering scientific organisations. As a result of the planned move to Cambridge, GSK will vacate its R&D site at Stevenage, Hertfordshire, with a phased move for employees by 2029. GSK will also upgrade its existing R&D laboratories at Ware in Hertfordshire and move some employees there to create a fully integrated drug development and commercial manufacturing scale up capability. The company plans to invest £400 million over 3 years in support of these changes. GSK will retain its global headquarters in London, which is unaffected by today's announcement. The investment is part of GSK's wider commitment to the UK life sciences ecosystem, with the company investing over £6 billion in R&D every year, of which more than £1.5 billion is in the UK. The Rutherford Post UK

LifeSci Voice
Jul 30th, 2026
Included Health agrees to acquire Firefly Health to expand employer health plan alternatives.

Included Health agrees to acquire Firefly Health to expand employer health plan alternatives. GSK will increase its R&D efforts by investing £400 million in Britain over three years. July 30, 2026 British pharmaceutical and biotechnology firm GSK has announced a comprehensive investment plan in the United Kingdom's pharmaceutical and biotechnology industry. This three-year, £400 million ($531 million) investment will take a significant step to advance its research and development pipeline rapidly. An integral part of this broad strategic restructuring is the transfer of the company's main R&D activities to Cambridge, one of the leading life sciences cities in the country. The massive allocation of capital is a key element of a new operational paradigm being implemented under the leadership of newly appointed CEO Luke Miels, who is spearheading an initiative focused on streamlining drug discovery, maximizing scientific productivity and delivering innovative, highly competitive medicines to market faster. The centrepiece of the programme will be a new, state-of-the-art, 300,000-square-foot site in Cambridge, eastern England, where GSK will build a new facility. The cutting-edge centre will house and enable over 1,000 scientists, technical experts and special research staff across the various therapeutic focus areas, such as oncology and respiratory diseases, to work. To cater for this long-term move, GSK will be leaving its long-established R&D facility in Stevenage, southern England, by 2029. At the same time, the company will modernise its existing site in Ware and move some of its current Stevenage team there as well. Although the company has made long-distance moves to its scientific institutes, GSK said its global corporate headquarters will still be "solidly London-based". The large investment will have a significant impact on the British economy, and is directly linked to the government's ambitious Life Sciences Sector Plan to make Britain one of the world's top three life sciences economies by 2035. The sector has successfully attracted over £3 billion in total life sciences investment in the last 12 months. GSK's move was welcomed by British Prime Minister Andy Burnham, who described it as a vote of confidence in home enterprise which could help to nurture local innovation, build on specialist scientific skills and boost the country's economy. GSK's announcement comes after a sustained stretch of activity and momentum within the UK healthcare sector as a whole. In a move that effectively undermines the previous decision, rival pharmaceutical company AstraZeneca has announced a £300m investment in Britain earlier this year after a previous plan to halt large-scale investments in this country was halted in response to previous economic worries. Moreover, GSK's investment comes only a few months after the United States and Britain reached a bilateral deal to raise UK drug prices, mirroring the new U.S. pricing policies of President Donald Trump. GSK anticipates that the cutting-edge Cambridge facility will continue to be integral and game-changing in the company's global competitiveness. The special investment will directly drive the R&D work forward, enabling the delivery of innovative and effective medical products quickly, said CEO Luke Miels. Overall, GSK remains one of the world's biggest spenders on pharmaceutical research, investing more than £6 billion on R&D each year, of which more than £1.5 billion is spent directly in the UK annually. GSK has announced plans to invest £400 million in research and development (R&D) across Britain over the next three years. The investment highlights GSK's long-term commitment to scientific innovation, advanced drug discovery, and strengthening the United Kingdom's position as a global life sciences hub. The funding is expected to accelerate medical research, expand R&D infrastructure, and support the development of innovative therapies for patients worldwide. Why the GSK investment matters. The new investment reinforces GSK's strategy of expanding its research capabilities while supporting the UK's growing biotechnology and pharmaceutical ecosystem. By increasing funding for R&D, GSK aims to accelerate scientific discoveries, improve clinical development, and strengthen collaborations with research institutions and healthcare partners. Discover more Government Agencies Manufacturing Food & Drink Discover more Machine Learning & Artificial Intelligence Pharmaceuticals Engineering & Technology Hansoh Pharmaceutical has recorded another late-stage success for its B7-H3-targeting antibody-drug conjugate (ADC), developed in partnership with GSK, after... Altimmune has reported topline results from its Phase 2 RECLAIM trial evaluating pemvidutide, an investigational dual GLP-1/GIP receptor agonist,... Virtual care and health navigation company Included Health has agreed to acquire Firefly Health as it seeks to scale... This week is set to be a pivotal one... In the middle of the debate about the Alzheimer's drug approval, the United States FDA has authorized Aduhelm Virtual care and health navigation company Included Health has... Forte Biosciences is being acquired by Argenx for $2.2... Since the two first joined forces in oncology three... Samsung Biologics has announced plans to acquire Swiss contract...